Related Experiment Video
Updated: Feb 24, 2026
Perturbing Endothelial Biomechanics via Connexin 43 Structural Disruption
Published on: October 4, 2019
Nanoencapsulated senotherapeutic compounds targeting connexin-43 for enhanced wound healing
Marina Rodríguez-Candela Mateos1, Jenifer García-Fernández2, Sofia M Saraiva2
1Institute of Biomedical Research of A Coruña (INIBIC), Complexo Hospitalario Universitario de A Coruña (CHUAC), SERGAS, A Coruña 15006, Spain.
Abstract:
Oncological patients receiving radiotherapy or chemotherapy often experience impaired wound healing due to tissue damage and cellular senescence. Connexin43 (Cx43) is a key regulator in this process, promoting senescence and the SASP, which hinder regeneration. This study investigates targeting Cx43 in primary dermal fibroblasts from cancer patients using a new combination of nanoencapsulated drugs. We show that Cx43 overexpression correlates with reduced gap junction communication, increased senescence, and delayed healing. Treatment with oleuropein (OLP), a polyphenol with antioxidant and regenerative properties, restores fibroblast function, reduces senescence, and improves healing. We also examine the p38 MAPK inhibitor BIRB796, alone and with OLP, demonstrating its ability to suppress SASP and support tissue repair. After confirming the superior combined effect of OLP and BIRB796, we developed a co-encapsulated nanoformulation. This innovative approach may significantly enhance wound healing in oncological patients.
Insights
Targeting Connexin43 (Cx43) with nanoencapsulated drugs improves wound healing in cancer patients. This novel approach uses oleuropein and a p38 MAPK inhibitor to restore fibroblast function and promote tissue regeneration.
Area of Science:
- Cell Biology
- Biomedical Engineering
- Oncology
Background:
- Radiotherapy and chemotherapy impair wound healing in cancer patients.
- Cellular senescence and the senescence-associated secretory phenotype (SASP) driven by Connexin43 (Cx43) hinder tissue regeneration.
- Cx43 overexpression is linked to reduced communication, senescence, and delayed healing in cancer patient fibroblasts.
Purpose of the Study:
- To investigate targeting Cx43 in cancer patient fibroblasts using nanoencapsulated drugs.
- To evaluate the efficacy of oleuropein (OLP) and a p38 MAPK inhibitor (BIRB796) in restoring fibroblast function and promoting wound healing.
- To develop and assess a co-encapsulated nanoformulation for enhanced therapeutic delivery.
Main Methods:
- Primary dermal fibroblasts from cancer patients were used.
- Cx43 expression, gap junction communication, senescence markers, and SASP factors were analyzed.
- Fibroblasts were treated with oleuropein (OLP), BIRB796, or a combination, both in free form and nanoencapsulated.
- Wound healing assays were performed to assess regenerative capacity.
Main Results:
- Cx43 overexpression correlated with impaired fibroblast function, increased senescence, and delayed healing.
- Oleuropein (OLP) treatment restored fibroblast function, reduced senescence, and improved healing.
- BIRB796 suppressed SASP and supported tissue repair, with superior combined effects when used with OLP.
- A co-encapsulated nanoformulation of OLP and BIRB796 demonstrated enhanced therapeutic potential.
Conclusions:
- Targeting Cx43 with OLP and BIRB796 offers a promising strategy to improve wound healing in oncological patients.
- Nanoencapsulation enhances the delivery and efficacy of these therapeutic agents.
- This innovative approach holds significant potential for enhancing regenerative medicine in cancer care.
